Compass Therapeutics (CMPX) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | D. Boral Capital Maintains Buy on Compass Therapeutics, Maintains $32 Price Target
BenzingaFeb 25 09:14 ET
Compass Stock Gains Amid Guggenheim Buy Rating
Seeking AlphaFeb 24 14:39 ET
Compass Therapeutics Initiated at Buy by Guggenheim
Dow JonesFeb 24 09:52 ET · Ratings
Guggenheim Initiates Compass Therapeutics(CMPX.US) With Buy Rating, Announces Target Price $12
Moomoo NewsFeb 24 07:31 ET · Ratings
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
BenzingaFeb 19 10:39 ET
Piper Sandler Initiates Compass Therapeutics at Overweight
MT NewswiresFeb 19 09:06 ET

Comments

Amp

Jan 8 09:38

$Compass Therapeutics (CMPX.US)$ This one could care leas that the market is down lol

1

Jaguar8

Jan 8 09:25

NEWS

$Compass Therapeutics (CMPX.US)$
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
Wednesday, 8th January at 8:00 am
• Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.
• CTX-10726 (a novel PD-1 x VEGF-A bispecific) is advancing as a new drug candidate after a year of preclinical development, with YE 2025 IND expected.
• Two...

2

Jaguar8

Oct 4, 2024 10:42

NEWS

$Compass Therapeutics (CMPX.US)$
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, announced the acceptance of an abstract for poster presentation at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. The meeting will be held from November 8–10, 2024, in Houston, TX.
The poster presentation, titled 'Pharmaco...

Jaguar8

Apr 16, 2024 07:02

$Compass Therapeutics (CMPX.US)$
NEWS
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics dosed the first patient in the Phase 1 trial of CTX-8371, a novel dual checkpoint blocker targeting PD-1 and PD-L1 in patients with solid tumors. The study aims to evaluate the drug's efficacy in patients who failed prior checkpoint blocker treatments.

1

Moomoo Breakfast US

May 4, 2022 07:22

Columns Today's pre-market stock movers: AMD, SBUX, ABNB, MRNA and more

Gainers:
• $Livent (LTHM.US)$ +22.58% (it posted better-than-expected quarterly earnings and raised its 2022 revenue forecast)
• $Super Micro Computer (SMCI.US)$ +11.01% (earnings reports)
• $Oatly Group AB (OTLY.US)$ +8.31% (earnings reports)
• $BlueLinx Holdings (BXC.US)$ +9.7% (increases share repurchase authorization to $100 mln; enters into $60 mln accelerated repurchase agreement)
• $Starbucks (SBUX.US)$ +7.18% (matched estimates wi...

27

1

5

CMPX Compass Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks